stockrowNasus Pharma Ltd.
NSRXHealthcare Drug Manufacturers General
Follow NSRX
Alert me
Nasus Pharma Ltd. (NSRX) Return on invested capital
Nasus Pharma Ltd.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, up 207.5 percentage points from fiscal 2025 (−207.5%). That is below the Drug Manufacturers General industry median of 6.26% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −207.5% | (207.52) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| OGN Organon & Co. compare | 6.26% |
| GRFS Grifols, S.A. compare | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| NSRX Nasus Pharma Ltd. | 0.00% |
| SCLX Scilex Holding Company compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −16.6% |
| MDCX Medicus Pharma Ltd compare | −2,497.5% |
| MIRA MIRA Pharmaceuticals, Inc. compare | −12,016.1% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)